Cancer Approval Standards, FDA Reputation At Stake With Avastin Hearing, NEJM Authors Say

In separate perspective pieces in the New England Journal of Medicine, Boston academics criticize the 2008 approval of bevacizumab's breast cancer claim based on progression-free survival and warn the agency's credibility will be undermined if the claim is not withdrawn.